Predictive Effectiveness of Circulating Tumor DNA in Recurrent Early-Stage Non-Small Cell Lung Cancer: An Updated...

Area of Science:

• Oncology
• Molecular Diagnostics
• Genomics

Background:

• Lung cancer is a leading cause of cancer mortality globally.
• Early-stage non-small cell lung cancer (NSCLC) carries a significant risk of recurrence post-surgery.
• Circulating tumor DNA (ctDNA) detection of minimal residual disease (MRD) is a promising biomarker for relapse prediction.

Purpose of the Study:

• To systematically evaluate the diagnostic performance of ctDNA-based MRD testing for recurrence detection in postoperative NSCLC.
• To assess the survival prediction capabilities of ctDNA MRD testing.
• To compare the effectiveness of tumor-informed versus tumor-agnostic ctDNA detection strategies.

Main Methods:

• A systematic meta-analysis of 30 studies involving 3,287 patients with postoperative NSCLC.
• Quality assessment of studies using the QUADAS-2 tool.
• Pooled diagnostic estimates calculated using bivariate random-effects models.
• Subgroup analyses of tumor-informed and tumor-agnostic strategies at landmark and longitudinal time points.

Main Results:

• Tumor-informed assays showed higher specificity and AUC in landmark analyses compared to tumor-agnostic approaches.
• Tumor-agnostic methods exhibited slightly higher sensitivity in landmark analyses.
• In longitudinal monitoring, tumor-informed assays maintained higher specificity, while tumor-agnostic methods showed higher sensitivity and AUC.

Conclusions:

• ctDNA-based MRD testing provides clinically significant prognostic information for early-stage NSCLC recurrence.
• Both tumor-informed and tumor-agnostic ctDNA strategies have complementary strengths.
• ctDNA MRD testing can potentially enhance postoperative surveillance and guide personalized treatment strategies for NSCLC patients.